Skip Ribbon Commands
Skip to main content
Sign In

24744 Plasma Cell Proliferative Disorder FISH, Bone Marrow (PCPDS)

Plasma Cell Proliferative Disorder FISH, Bone Marrow (PCPDS)
Test Code: PCPDFSO
Synonyms/Keywords
+1q or 1q22
17p- (17p deletion) or TP53
IGH (14q32) rearrangement
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple Myeloma
Plasma Cell Leukemia
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
t(4;14) - FGFR3/IGH
Useful For
Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders
 
Identifying prognostic markers based on the anomalies found
 

When this test is ordered, pre-analysis cell sorting will be performed at an additional charge.

For diagnostic samples, all probes in the initial panel will be evaluated if sufficient plasma cells are identified. The initial panel includes testing for the following abnormalities using the probes listed:

17p-, TP53/D17Z1

1q gain, TP73/1q22

14q32 rearrangement, IGH

Based on the results from the initial panel, reflex testing may be performed to identify the following abnormalities using the probes listed:

t(11;14), CCND1/IGH

t(14;16)(q32;q23) IGH/MAF

t(4;14)(p16.3;q32) FGFR3/IGH

t(14;20)(q32;q12) IGH/MAFB 

For follow-up samples, only TP73/1q22, TP53/D17Z1 and MYC probes will be tested. If a diagnostic sample was uninformative for a probe set due to an insufficient number of plasma cells, attempts may be made to achieve results for the missing probe on a subsequent sample (if sufficient plasma cells are identified).

Initial screening will be performed to determine if sufficient plasma cells are present within the provided specimen.

If the specimen is received greater than 96 hours from collection, or arrives clotted or hemolyzed, this test will be canceled and MFCF / Myeloma, FISH, Fixed Cells will be added as the more appropriate test.

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Bone Marrow ACD Yellow top tube (YTT)

​EDTA Lavender top tube (LTT)

Heparin Green top tube (GTT)

​4 mL ​2 mL
Collection Processing Instructions
Invert several times to mix bone marrow.
Specimen should arrive within 96 hours of collection.
 
Necessary Information:
1. Provide a reason for testing with each specimen. The laboratory will not reject testing if this information is not
provided but appropriate testing and interpretation may be compromised or delayed.
2. A pathology and/or flow cytometry report may be requested to optimize testing and aid in interpretation of results.
Specimen Stability Information
Specimen Type Temperature​Time
​Bone Marrow ​ ​Ambient (preferred)​4 days
​Refrigerated​4 days
Rejection Criteria
No specimen should be rejected
Interference

​Advisory Information:
This assay detects high risk abnormalities plus CCND1/IGH fusion observed in the bone marrow of patients with a plasma cell disorder.

-For a more complete genetic evaluation, order MPCDS / mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow.

-For paraffin-embedded tissue specimens, order PLASF / Plasma Cell Proliferative Disorder, FISH, Tissue.

-For fixed cell pellet specimens, order MFCF / Myeloma, FISH, Fixed Cells.

-Testing will be changed to the appropriate test if this test is ordered on either of the previous specimens or if bone marrow specimens are received more than 96 hours from collection.

Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories
Monday through Friday
7 days​
Fluorescence In Situ Hybridization (FISH)
Reference Lab
Test Information

Multiple myeloma is a hematologic neoplasm that generally originates in the bone marrow and develops from malignant plasma cells. There are four main categories of plasma cell proliferative disorders (PCPD): monoclonal gammopathy of undetermined significance (MGUS), monoclonal immunoglobulin deposition diseases (amyloidosis), plasmacytoma, and multiple myeloma. MGUS, which occurs in 3% to 4% of individuals over age 50 years, represents the identification of an asymptomatic monoclonal protein, yet approximately 1% per year will progress to multiple myeloma. Amyloidosis represents a rare group of deposition disorders including primary amyloidosis vs. light chain and heavy chain disease. Plasmacytomas represent isolated collections of bone or extramedullary plasma cells with a risk for development of multiple myeloma. Generalized bone pain, anemia, limb numbness or weakness, symptoms of hypercalcemia, and recurrent infections are all symptoms that may indicate multiple myeloma.

As myeloma progresses, the malignant plasma cells interfere with normal blood product formation in the bone marrow resulting in anemia and leukopenia. Myeloma also causes an overstimulation of osteoclasts, causing excessive breakdown of bone tissue without the normal corresponding bone formation. These bone lesions are seen in approximately 66% of myeloma patients. In advanced disease, bone loss may reach a degree where the patient suffers fractures easily.

Multiple myeloma is increasingly recognized as a disease characterized by marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested clinically by varying degrees of disease aggressiveness. Multiple myeloma patients with more aggressive disease experience suboptimal responses to some therapeutic approaches; therefore, identifying these patients is critically important for selecting appropriate treatment options.

Reference Range Information
An interpretive report will be provided.
Interpretation
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​​88291 ​1 DNA probe, each (first probe set), Interpretation and report
​88271 2
DNA probe, each (first probe set), Interpretation and report
​88271 2 DNA probe, each; each additional probe set (if appropriate)
​88271 ​1 ​DNA probe, each; coverage for sets containing 3 probes (if appropriate)
​88271 ​2 ​​DNA probe, each; coverage for sets containing 4 probes (if appropriate)
​88271​ ​3 ​DNA probe, each; coverage for sets containing 5 probes (if appropriate)
​​88274-52 ​1 ​Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
​88274​ ​1 ​Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
​88275​ ​1 ​​Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)
Synonyms/Keywords
+1q or 1q22
17p- (17p deletion) or TP53
IGH (14q32) rearrangement
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple Myeloma
Plasma Cell Leukemia
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
t(4;14) - FGFR3/IGH
Ordering Applications
Ordering Application Description
​Centricity ​PCPD, FISH (PCPDS)
​Cerner ​Plasma Cell Proliferative Disorder, FISH (PCPDS)
​COM​Plasma Cell Prolif, FISH
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Bone Marrow ACD Yellow top tube (YTT)

​EDTA Lavender top tube (LTT)

Heparin Green top tube (GTT)

​4 mL ​2 mL
Collection Processing
Invert several times to mix bone marrow.
Specimen should arrive within 96 hours of collection.
 
Necessary Information:
1. Provide a reason for testing with each specimen. The laboratory will not reject testing if this information is not
provided but appropriate testing and interpretation may be compromised or delayed.
2. A pathology and/or flow cytometry report may be requested to optimize testing and aid in interpretation of results.
Specimen Stability Information
Specimen Type Temperature​Time
​Bone Marrow ​ ​Ambient (preferred)​4 days
​Refrigerated​4 days
Rejection Criteria
No specimen should be rejected
Interference

​Advisory Information:
This assay detects high risk abnormalities plus CCND1/IGH fusion observed in the bone marrow of patients with a plasma cell disorder.

-For a more complete genetic evaluation, order MPCDS / mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow.

-For paraffin-embedded tissue specimens, order PLASF / Plasma Cell Proliferative Disorder, FISH, Tissue.

-For fixed cell pellet specimens, order MFCF / Myeloma, FISH, Fixed Cells.

-Testing will be changed to the appropriate test if this test is ordered on either of the previous specimens or if bone marrow specimens are received more than 96 hours from collection.

Useful For
Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders
 
Identifying prognostic markers based on the anomalies found
 

When this test is ordered, pre-analysis cell sorting will be performed at an additional charge.

For diagnostic samples, all probes in the initial panel will be evaluated if sufficient plasma cells are identified. The initial panel includes testing for the following abnormalities using the probes listed:

17p-, TP53/D17Z1

1q gain, TP73/1q22

14q32 rearrangement, IGH

Based on the results from the initial panel, reflex testing may be performed to identify the following abnormalities using the probes listed:

t(11;14), CCND1/IGH

t(14;16)(q32;q23) IGH/MAF

t(4;14)(p16.3;q32) FGFR3/IGH

t(14;20)(q32;q12) IGH/MAFB 

For follow-up samples, only TP73/1q22, TP53/D17Z1 and MYC probes will be tested. If a diagnostic sample was uninformative for a probe set due to an insufficient number of plasma cells, attempts may be made to achieve results for the missing probe on a subsequent sample (if sufficient plasma cells are identified).

Initial screening will be performed to determine if sufficient plasma cells are present within the provided specimen.

If the specimen is received greater than 96 hours from collection, or arrives clotted or hemolyzed, this test will be canceled and MFCF / Myeloma, FISH, Fixed Cells will be added as the more appropriate test.

Reference Range Information
An interpretive report will be provided.
Interpretation
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories
Monday through Friday
7 days​
Fluorescence In Situ Hybridization (FISH)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​​88291 ​1 DNA probe, each (first probe set), Interpretation and report
​88271 2
DNA probe, each (first probe set), Interpretation and report
​88271 2 DNA probe, each; each additional probe set (if appropriate)
​88271 ​1 ​DNA probe, each; coverage for sets containing 3 probes (if appropriate)
​88271 ​2 ​​DNA probe, each; coverage for sets containing 4 probes (if appropriate)
​88271​ ​3 ​DNA probe, each; coverage for sets containing 5 probes (if appropriate)
​​88274-52 ​1 ​Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
​88274​ ​1 ​Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
​88275​ ​1 ​​Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)
For most current information refer to the Marshfield Laboratory online reference manual.